Recently, Suzhou ZKEY BioTech Development Co., Ltd. proudly announced the successful closure of its multi-million-yuan Pre-A round financing, with Changchun Changxing Fund stepping in as the key investor. Since its inception in December 2022, ZKEY BioTech has consistently attracted investments from notable entities such as Guoke Venture Capital and Changchun Changxing Fund.

The company is at the forefront of diagnosing and treating aging-related diseases and addressing general health needs, leveraging its core nanotechnology expertise. Adopting a dual-pronged strategy of "exosome diagnostics + medical aesthetics and general health," ZKEY BioTech has established two pivotal technology platforms. It has made significant strides in the realms of in vitro diagnostics and anti-aging general health, thereby fostering a diversified growth trajectory.

The founder of the company, Yang Yanlian, has been instrumental in shaping the national standard system for exosomes and contributing to the formulation of ISO international standards. Presently, the exosome industry is poised at a pivotal juncture in its evolution. By harnessing technological innovation and setting industry standards, ZKEY BioTech, in collaboration with Changxing Fund, is set to explore new frontiers within the industry, with the ambition of emerging as a frontrunner in the exosome diagnostics, treatment, and general health sector.